Vaxcyte
PCVX
66.96
+0.26
+0.39%
Vaxcyte
US · PCVX
#1630 by market cap
Listed 2020
66.96
+0.26
+0.39%
Live - 5344 symbols - heartbeat 132s ago
· 2026-10-08 07:36
Pre-market
66.78
-0.27%
After-hours
66.60
-0.54%
Overnight
66.59
-0.55%
- Market cap
- 9.96B
- P/E (TTM)i
- -8.78
- P/Bi
- 3.61
- EPSi
- -5.63
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on PCVX?
Anonymous reader poll. Unscientific, not investment advice.
About Vaxcyte
Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.
- Founded
- 2013
- CEO
- Mr. Grant E. Pickering
- Employees
- 507
- Headquarters
- San Carlos, California, United States of America
- Fiscal year end
- 12-31
- Website
- vaxcyte.com
Company profile
- Exchange
- US
- Symbol
- PCVX
- Market-cap rank
- #1630
- Listing date
- 2020-06-12
- Market cap
- 9.96B
- Float cap
- 9.14B
- Shares out
- 148.81M
- Float shares
- 136.44M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-10-08 07:36:37 · For reference only, not investment advice and not tailored to your situation.